QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Drobnic, M E. Articles by Orriols, R. Search for Related Content PubMed PubMed Citation Articles by Drobnic, M E. Articles by Orriols, R.

INFECTIOUS DISEASES

Inhaled Tobramycin in Non–Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas aeruginosa

Pneumologist, Pneumology Service, Department of Medicine, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain

Pilar Suñé, PharmD

Clinical Pharmacist, Pharmacy Service, Hospital Vall d'Hebron

J Bruno Montoro, PhD

Clinical Pharmacist, Pharmacy Service, Hospital Vall d'Hebron

Adelaida Ferrer, MD

Microbiologist, Microbiology Service, Hospital Vall d'Hebron

Ramon Orriols, MD

Pneumologist, Pneumology Service, Hospital Vall d'Hebron

Reprints: Dr. Montoro Ronsano, Servei de Farmàcia, Hospital General Vall d'Hebron, Passeig Vall d'Hebron, 119-129; 08035 Barcelona, Spain, fax 34-93-2746046, bmontoro{at}vhebron.net

BACKGROUND: Non–cystic fibrosis (CF) patients with bronchiectasis usually develop chronic bronchial infection with Pseudomonas aeruginosa (PA) that is related to worsening lung function and increased morbidity and mortality.

OBJECTIVE: To determine whether direct aerosol delivery of tobramycin to the lower airways may control infection and produce only low systemic toxicity.

METHODS: A double-blind, placebo-controlled crossover trial involving 30 patients was conducted to determine the clinical effectiveness and safety of 6-month tobramycin inhalation therapy. Patients received 300 mg of aerosolized tobramycin or placebo twice daily in 2 cycles, each for 6 months, with a one-month washout period. The number of exacerbations, number of hospital admissions, number of hospital admission days, antibiotic use, pulmonary function, quality of life, tobramycin toxicity, density of PA in sputum, emergence of bacterial resistance, and emergence of other opportunistic bacteria were recorded.

RESULTS: The number of admissions and days of admission (mean ± SD) during the tobramycin period (0.15 ± 0.37 and 2.05 ± 5.03) were lower than those during the placebo period (0.75 ± 1.16 and 12.65 ± 21.8) (p < 0.047). A decrease in PA density in sputum was associated with tobramycin administration in the analysis of the first 6-month cycle (p = 0.038). No significant differences were observed in the number of exacerbations, antibiotic use, pulmonary function, and quality of life. The emergence of bacterial resistance and other bacteria did not differ between the 2 periods of study. Inhaled tobramycin was associated with bronchospasm in 3 patients, but not with detectable ototoxicity or nephrotoxicity.

CONCLUSIONS: Aerosol administration of high-dose tobramycin in non-CF bronchiectatic patients for endobronchial infection with PA appears to be safe and decreases the risk of hospitalization and PA density in sputum. Nevertheless, pulmonary function and quality of life are not improved, and the risk of bronchospasm is appreciable.

Key Words: bronchiectasis, inhaled tobramycin, Pseudomonas aeruginosa

Published Online, November 23, 2004. www.theannals.com, DOI 10.1345/aph.1E099

This article has been cited by other articles:

				A B Chang and D Bilton Exacerbations in cystic fibrosis: 4 {middle dot} Non-cystic fibrosis bronchiectasis Thorax, March 1, 2008; 63(3): 269 - 276. [Abstract] [Full Text] [PDF]

				C. A. Cannella and S. T. Wilkinson Acute renal failure associated with inhaled tobramycin. Am. J. Health Syst. Pharm., October 1, 2006; 63(19): 1858 - 1861. [Abstract] [Full Text] [PDF]